Obesity Drug Trial Put On Hold Due To Second Patient Death.

reports that the move was a “major setback” to Zafgen’s “bid to become an obesity drug pioneer.” Both patients who died during the trial were confirmed to have been taking beloranib, rather than a placebo. The AP (12/3) reports that Zafgen “said the patient died from a blockage in an artery in the lung, or blood clots, in the late-stage study of beloranib.” Reuters (12/3, Nathan) also covers the story. http://www.bloomberg.com/news/articles/2015-12-02/zafgen-plummets-after-second-patient-died-on-obesity-drug